Results of a sub-study of the phase III CheckMate-901 trial showed that Opdivo (nivolumab) in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy demonstrated statistically significant benefits in OS and PFS compared to standard-of-care cisplatin-based combinations as a first-line treatment for patients with unresectable or metastatic urothelial carcinoma who are eligible for cisplatin-based chemotherapy.
Positive high-level results from the TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.
A study shows that an artificial intelligence model co-developed by researchers in the UCLA Jonsson Comprehensive Cancer Center and department of Urology at UCLA can help doctors determine the extent of cancer within the prostate.
Positive top-line results from the pivotal BLUE-C study showed that the next-generation Cologuard met all study endpoints and improved every top-line metric, including a 30% lower false positive rate compared to DeeP-C, the FDA registrational trial for Cologuard.
Results from an international clinical trial, published June 15 in The Lancet, show that the selective targeted therapy, fruquintinib resulted in a statistically significant improvement in overall survival and progression-free survival.
Led by Stanford University School of Medicine’s Department of Urology, researchers found that Avenda Health’s machine learning model, Unfold AI, and novel cancer probability metric was shown to be accurate and effective in identifying the extent of the cancer, not just location.
A genetic marker discovered by UT Southwestern Medical Center researchers could help physicians predict which patients with hepatocellular carcinoma are most likely to develop resistance to the drug lenvatinib.
Updated efficacy and safety results from a phase II single-arm trial (SGN35-027) evaluating the antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma showed a 98% overall response rate and a 93% complete response rate at the end of treatment.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a trio of immune cells within tumor niches that are associated with immunotherapy response in hepatocellular carcinoma.
People experiencing racial discrimination are more reluctant to get vaccinations, according to a study conducted by researchers at the University of Arkansas for Medical Sciences Office of Community Health & Research.
